Janus Henderson Group
ELDN icon

Janus Henderson Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Janus Henderson Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-245,095
Closed -$1.93M – 2202
2021
Q2 		$1.93M Buy
245,095
+31,196
+15% +$294K ﹤0.01% 1243
2021
Q1 		$2.25M Buy
+213,899
New +$3.23M ﹤0.01% 1164

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group's ELDN Position: Q3 2021 in Review

Janus Henderson Group sold out of Eledon Pharmaceuticals (ELDN) in Q3 2021, closing a stake of 245,095 shares — an estimated $1.93M sold.

Janus Henderson Group first reported a position in ELDN in Q1 2021 and held it in 2 quarters. The position peaked at $2.25M in Q1 2021. 35 funds tracked by Wall St. Rank hold ELDN as of Q3 2021.

  • Janus Henderson Group reported no remaining Eledon Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Janus Henderson Group sold 245,095 Eledon Pharmaceuticals shares in Q3 2021, an estimated $1.93M.
  • Janus Henderson Group first reported a position in Eledon Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Janus Henderson Group's Eledon Pharmaceuticals position peaked at $2.25M in Q1 2021.
  • 35 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2021.

Based on Janus Henderson Group's 13F filing for Q3 2021, filed 16 Nov 2021.